Targeted literature review of the burden of extraintestinal pathogenic Escherichia Coli among elderly patients in Asia Pacific regions.

BACKGROUND Extraintestinal Pathogenic Escherichia coli (ExPEC) is a leading cause of invasive disease, including bacteremia and sepsis. Invasive ExPEC disease (IED) has the potential to complicate the clinical treatment of other conditions and is associated with an increased mortality, hospitalization, and worse outcomes. Older adults and individuals with comorbid conditions are at higher risk of IED. ExPEC is of particular concern in the Asia Pacific region due to aging populations and rising antimicrobial resistance. OBJECTIVES This study aimed to synthesize most recent data on the epidemiology, clinical and economic burden of IED in the elderly/high risk populations in China, Japan, South Korea, Taiwan, and Australia. METHODS A targeted literature review was conducted using Embase, Medline as well as local scientific databases. We included studies published in English and local languages published from January 1, 2010 to October 7, 2020 that were relevant to the research objectives. Studies were narratively synthesized. RESULTS A total of 1,047 studies were identified and 34 of them were included in this review. ExPEC accounted for 46.0% (1,238/2,692) of bacteria-related invasive diseases in patients aged above 60 years in South Korea, followed by China (44.4% (284/640)), Taiwan (39.0% (1,244/3,194)), and Japan (18.1% (581/3,206)), while Australia reported ExPEC out of all pathogens (54.7% (4,006/7,330)) in general adults. Comorbidities such as diabetes or cancer were common in these patients. Studies reported increases in length-of-stay, and in-hospital 30-day all-cause mortality related to ExPEC associated bacteremia was between 9% to 12%. From a cost perspective, a 3-fold increase in sepsis-associated cost was reported in South Korea between 2005 and 2012. In Australia, antimicrobial resistance contributed to an additional cost of AUD $5.8 million per year (95% uncertainty interval [UI], $2.2-$11.2 million) in the treatment of bloodstream infections (BSIs). CONCLUSION ExPEC was a major cause of blood stream infection across China, Japan, South Korea, Taiwan, and Australia. Both the clinical and economic burden associated to ExPEC infections as well as the antimicrobial resistance observed in the elderly call for preventive and curative actions in these regions.Key summary pointsExtraintestinal Pathogenic Escherichia coli (ExPEC) is a leading cause of invasive disease, including bacteremia and sepsis.A targeted literature review included the most recent data from 34 published studies on the epidemiology and clinical and economic burden of IED in the elderly/high risk populations in China, Japan, South Korea, Taiwan, and Australia.ExPEC accounted for 46.0% (1,238/2,692) of bacteria-related invasive diseases in patients aged above 60 years in South Korea, followed by China (44.4% (284/640)), Taiwan (39.0% (1,244/3,194)), and Japan (18.1% (581/3,206)), while Australia reported ExPEC out of all pathogens (54.7% (4,006/7,330)) in general adults. Studies reported increases in length-of-stay and in-hospital 30-day all-cause between 9% to 12%. These factors along with antimicrobial resistance observed in the elderly call for preventive and curative actions in these regions.Data for costs associated with ExPEC induced BSI or sepsis in this region are limited, but evidence shows increasing expenditures.

[1]  Tetsuya Matsumoto,et al.  Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan , 2021, Journal of health economics and outcomes research.

[2]  K. Yahara,et al.  Disease burden of bloodstream infections caused by antimicrobial-resistant bacteria: a population-level study-Japan, 2015-2018 , 2021, medRxiv.

[3]  H. Akiyama Aging well: an update. , 2020, Nutrition reviews.

[4]  M. Bonten,et al.  Epidemiology of Escherichia coli Bacteremia: A Systematic Literature Review. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  K. Yanagihara,et al.  Multicenter surveillance of the epidemiology of gram-negative bacteremia in Japan. , 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  K. Yahara,et al.  National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[7]  Jijiang Suo,et al.  Bloodstream Infection and Its Clinical Characteristics and Relevant Factors Associated with Interventional Therapy in a Large Tertiary Hospital: A Six Years Surveillance Study , 2019, BioMed research international.

[8]  J. Shin,et al.  Antimicrobial resistance in South Korea: A report from the Korean global antimicrobial resistance surveillance system (Kor-GLASS) for 2017. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[9]  Yonghong Xiao,et al.  A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections. , 2019, Journal of global antimicrobial resistance.

[10]  Ziyong Sun,et al.  Antimicrobial resistance trends in bloodstream infections at a large teaching hospital in China: a 20-year surveillance study (1998-2017) , 2019, Antimicrobial Resistance & Infection Control.

[11]  N. Graves,et al.  Health and economic burden of antimicrobial-resistant infections in Australian hospitals: a population-based model , 2019, Infection Control & Hospital Epidemiology.

[12]  Soyeon Ahn,et al.  Epidemiology of sepsis in Korea: a population-based study of incidence, mortality, cost and risk factors for death in sepsis , 2019, Clinical and experimental emergency medicine.

[13]  Yingrui Zhang,et al.  Clinical Situations of Bacteriology and Prognosis in Patients with Urosepsis , 2019, BioMed research international.

[14]  Kyungwon Lee,et al.  Trends in South Korean antimicrobial use and association with changes in Escherichia coli resistance rates: 12-year ecological study using a nationwide surveillance and antimicrobial prescription database , 2018, PloS one.

[15]  Y. Niki,et al.  Epidemiology and risk factors for mortality in bloodstream infections: A single‐center retrospective study in Japan , 2018, American journal of infection control.

[16]  H. Hagiya,et al.  Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli. , 2018, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[17]  T. Kirita,et al.  Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan , 2018, PloS one.

[18]  J. Shin,et al.  Impact of host-pathogen-treatment tripartite components on early mortality of patients with Escherichia coli bloodstream infection: Prospective observational study , 2018, EBioMedicine.

[19]  W. Ko,et al.  Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[20]  X. Shao,et al.  Etiologic spectrum and occurrence of coinfections in children hospitalized with community-acquired pneumonia , 2017, BMC Infectious Diseases.

[21]  Y. Kaneko,et al.  Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital , 2017, Internal medicine.

[22]  Sihe Zhang,et al.  Bacteraemia due to AmpC β-lactamase-producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes. , 2017, Diagnostic microbiology and infectious disease.

[23]  N. Ohmagari,et al.  Unique characteristics of community-onset healthcare- associated bloodstream infections: a multi-centre prospective surveillance study of bloodstream infections in Japan. , 2017, The Journal of hospital infection.

[24]  M. Akova,et al.  High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China , 2017, The Journal of antimicrobial chemotherapy.

[25]  P. Fratamico,et al.  Advances in Molecular Serotyping and Subtyping of Escherichia coli , 2016, Front. Microbiol..

[26]  Y. Carmeli,et al.  The negative impact of antibiotic resistance. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[27]  J. Poolman,et al.  Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field , 2015, The Journal of infectious diseases.

[28]  C. Ryeon,et al.  Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131. , 2015 .

[29]  W. Hsieh,et al.  Epidemiology and Prevalence of Bloodstream Infections in a Regional Hospital in Northern Taiwan During 2008–2013 , 2014 .

[30]  K. Peck,et al.  Clinical characteristics and outcomes of community-onset acute pyelonephritis caused by Escherichia coli in elderly patients , 2014 .

[31]  Min Hyung Kim,et al.  Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia. , 2014, Archives of gerontology and geriatrics.

[32]  K. Peck,et al.  Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. , 2013, International journal of antimicrobial agents.

[33]  M. Nagao A multicentre analysis of epidemiology of the nosocomial bloodstream infections in Japanese university hospitals. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  D. Paterson,et al.  Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Hyo Youl Kim,et al.  Epidemiological and Clinical Characteristics of Community-Acquired Severe Sepsis and Septic Shock: A Prospective Observational Study in 12 University Hospitals in Korea , 2012, Journal of Korean medical science.

[36]  W. Ko,et al.  Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community. , 2012, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[37]  J. Cho,et al.  Risk factors of septic shock in bacteremic acute pyelonephritis patients admitted to an ER , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[38]  K. Ko,et al.  Bloodstream Infections and Clinical Significance of Healthcare-associated Bacteremia: A Multicenter Surveillance Study in Korean Hospitals , 2010, Journal of Korean medical science.

[39]  S. Cosgrove,et al.  Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. , 2002, Archives of internal medicine.

[40]  Leibovici,et al.  The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection , 1998, Journal of internal medicine.